Zevra Therapeutics Inc
Zevra Therapeutics Inc (ZVRA) is a clinical-stage biotechnology company; its market capitalisation is approximately $623.10M. Investors should know it is a development-led business where value is driven by research milestones, regulatory decisions and partnership activity rather than recurring revenues. That profile means share moves can be sharp around trial readouts, licensing announcements or quarterly cash updates. Typical considerations for prospective investors include the company’s pipeline stage, trial timelines, cash runway and potential for dilution if additional financing is required. As with many small-cap biotech firms, outcomes are binary and uncertainty is high: successful clinical data can create upside, while setbacks may materially reduce value. This summary provides general educational information and is not personalised investment advice; suitability depends on your objectives, time horizon and risk tolerance, so review regulatory filings and consult a professional if unsure.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zevra Therapeutics stock with a target price of $22.86, indicating strong growth potential.
Financial Health
Zevra Therapeutics is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ZVRA
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalyst-driven story
Trial readouts and regulatory milestones can move the share price sharply; outcomes are binary and performance can vary.
R&D and innovation
Value is shaped by the success of development programmes and partnerships, though R&D is costly and success is uncertain.
Size and liquidity
With a market cap near $623M, the stock can be more volatile and less liquid; consider diversification and your risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
